Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
Researchers have developed an improved industrial synthesis process for dehydration dihydroartemisinin, a critical intermediate in highly effective antimalarial medications. Traditional methods faced significant challenges including low product purity, complex operational procedures, poor reactant conversion rates, high production costs, and suboptimal yields, hindering large-scale manufacturing capability.
The inventive method fundamentally simplifies the production workflow while simultaneously enhancing efficiency and output quality. The optimized, three-step procedure commences with the sequential mixing of dichloromethane, triethylamine (N(C2H5)3), and phosphorus oxychloride (POCl3) within a reaction vessel. Dihydroartemisinin is then added incrementally in 5-7 separate portions under rigorously controlled conditions: the vessel is immersed in an ice-water bath with continuous stirring. Following controlled warming to room temperature, the reaction mixture undergoes an extended transformation period lasting between 11 to 17 hours.
In the crucial second phase, the resultant reaction solution undergoes quenching using ice-cold water. The mixture is methodically washed until achieving a moderately acidic pH range of 3-6, ensuring separation from acidic by-products. Effective dehydration is accomplished using anhydrous magnesium sulfate, yielding a purified dried solution ready for final processing.
The ultimate purification step employs thin-film evaporation concentration, significantly reducing solvent volume efficiently. The concentrated extract is further refined via silica gel chromatography, isolating the target compound. Subsequent vacuum concentration facilitates the crystallization process, yielding the final product as high-purity flake-like crystals of dehydration dihydroartemisinin.
Key advantages substantiated by the new protocol include dramatically higher single-pass reactant conversion rates and significantly increased product yield. The process circumvents the need for cumbersome post-reaction treatments endemic to earlier techniques. Its relative simplicity translates directly to lower operational costs and superior scalability for industrial deployment. Furthermore, it demonstrates an improved environmental profile by minimizing waste streams and eliminating hazardous intermediates utilized previously.
This technological leap holds profound implications for global malaria control efforts. Dehydration dihydroartemisinin serves as a vital precursor for artemisinin-based combination therapies (ACTs), the cornerstone of modern malaria treatment recommended by the World Health Organization. Streamlining its synthesis ensures a more robust, affordable, and accessible drug supply chain, directly supporting the fight against a disease affecting millions annually, particularly in resource-limited regions. The optimized process demonstrates enhanced feasibility for high-volume pharmaceutical production.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
